文献速递妇产影像泌尿生殖技术与安全PETMR

卵巢癌患者与非卵巢癌患者前列腺特异性膜抗原(PSMA)在PET-MRI上的分布

Distribution of prostate specific membrane antigen (PSMA) on PET-MRI in patients with and without ovarian cancer.
PubMed 文献 · Abdom Radiol (NY) · 2023-06-01

这项前瞻性先导概念验证研究于2017年10月至2020年1月纳入14例因妇科指征行子宫卵巢切除术的患者,术前行PSMA 18F-DCFPyl PET/MRI。卵巢癌(SUVmax=7.8±3.8)摄取高于血池、正常卵巢和良性卵巢病变,正常卵巢(2.8±0.4)摄取高于血池(1.8±0.5,p<0.0001),良性病变(2.2±1.0)与血池无显著差异(p=0.331)。作者认为结果令人鼓舞,需在更大患者队列中进一步研究。

要点

  • 卵巢癌PSMA摄取(SUVmax=7.8±3.8)高于血池、正常卵巢(p=0.0014)和良性卵巢病变(p=0.005)。
  • 良性卵巢病变PSMA摄取(2.2±1.0)与血池(1.8±0.5)无显著差异(p=0.331)。
  • 正常卵巢PSMA摄取(2.8±0.4)高于血池(1.8±0.5,p<0.0001)。

核心结论

  • PET/MRI可检出卵巢癌的PSMA摄取,良性卵巢病变摄取很少至几乎无摄取;作者认为结果令人鼓舞,需在更大患者队列中进一步研究以确定卵巢癌患者PSMA摄取的 extent 和异质性。

研究设计与样本

  • 前瞻性先导概念验证研究,2017年10月至2020年1月纳入14例因妇科指征行子宫和卵巢切除术的患者,术前行PSMA 18F-DCFPyl PET/MRI,以标准治疗手术为参考。

诊断标准与关键数值

  • 正常卵巢SUVmax=2.8±0.4,高于血池SUVmax=1.8±0.5(p<0.0001)。
  • 良性卵巢病变SUVmax=2.2±1.0,与血池无显著差异(p=0.331)。
  • 卵巢癌SUVmax=7.8±3.8,高于血池(p<0.0001)、正常卵巢(p=0.0014)和良性卵巢病变(p=0.005)。

临床应用与阅片要点

  • 作者认为结果令人鼓舞,需在更大患者队列中进一步研究以确定卵巢癌患者PSMA摄取的 extent 和异质性。

局限性

  • 作者指出需在更大患者队列中进一步研究以确定卵巢癌患者PSMA摄取的 extent 和异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Ovarian cancer is the most lethal cancer and future research needs to focus on the early detection and exploration of new therapeutic agents. The objectives of this proof-of-concept study are to assess the feasibility of PSMA 18F-DCFPyl PET/MR imaging for detecting ovarian cancer and to evaluate the PSMA distribution in patients with and without ovarian cancer.

METHODS: This prospective pilot proof-of-concept study in patients with and without ovarian cancers occurred between October 2017 and January 2020. Patients were recruited from gynecologic oncology or hereditary ovarian cancer clinics, and underwent surgical removal of the uterus and ovaries for gynecologic indications. PSMA 18F-DCFPyl PET/MRI was obtained prior to standard of care surgery.

RESULTS: Fourteen patients were scanned: four patients with normal ovaries, six patients with benign ovarian lesions, and four patients with malignant ovarian lesions. Tracer uptake in normal ovaries (SUVmax = 2.8 ± 0.4) was greater than blood pool (SUVmax = 1.8 ± 0.5, p < 0.0001). Tracer uptake in benign ovarian lesions (2.2 ± 1.0) did not differ significantly from blood pool (p = 0.331). Tracer uptake in ovarian cancer (SUVmax = 7.8 ± 3.8) was greater than blood pool (p < 0.0001), normal ovaries (p = 0.0014), and benign ovarian lesions (p = 0.005).

CONCLUSION: PET/MR imaging detected PSMA uptake in ovarian cancer, with little to no uptake in benign ovarian findings. These results are encouraging and further studies in a larger patient cohort would be useful to help determine the extent and heterogeneity of PSMA uptake in ovarian cancer patients.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Sadowski, Lees, McMillian, et al. Distribution of prostate specific membrane antigen (PSMA) on PET-MRI in patients with and without ovarian cancer. Abdom Radiol (NY). 2023. PMID: 37261441. doi:10.1007/s00261-023-03957-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。